Production and Clinical Evaluation of Norwalk GI.1 Virus Lot 001-09NV in Norovirus Vaccine Development.
Human noroviruses (HuNoV) are the leading cause of gastroenteritis. No vaccine is currently available to prevent norovirus illness or infection. Safe, infectious challenge strains are needed to assess vaccine efficacy in the controlled human infection model (CHIM). A stock of HuNoV strain Norwalk virus (GI.1) was prepared. Healthy, genetically susceptible adults were inoculated with Norwalk virus (NV) Lot 001-09NV and monitored for infection, gastroenteritis symptoms and immune responses. Lot 001-09NV induced gastroenteritis in 9 (56%) and infection in 11 (69%) of 16 genetically susceptible subjects. All infected subjects developed strong immune responses to GI.1 with a 30-fold (GMT) increase in blocking titers (BT50) and a 161-fold increase in GI.1-specific IgG titers when compared to baseline. GI.1-specific cellular responses in peripheral blood were observed 9 days post-challenge with an average of 3253 IgA and 1227 IgG antibody secreting cells (ASCs) per million PBMCs. GI.1 Lot 001-09NV appears to be similar in virulence to previous passages of Norwalk virus strain 8fIIa. The safety profile, attack rate, and duration of illness make GI.1 Lot 001-09NV a useful challenge strain for future vaccine studies aimed at establishing immune correlates.